Sym004, a novel anti-EGFR antibody mixture augments radiation response in human lung and head and neck cancers

Documenti analoghi

• Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
  di: Iida, Mari, et al.
  Pubblicazione: (2013)
• Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
  di: Huang, Shyhmin, et al.
  Pubblicazione: (2012)
• Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
  di: Keir, Stephen T., et al.
  Pubblicazione: (2018)
• Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines
  di: Fukuoka, Shota, et al.
  Pubblicazione: (2016)
• Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors
  di: Kojima, Takashi, et al.
  Pubblicazione: (2018)